Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Insight Molecular Diagnostics (IMDX) Other Non Operating Income (2020 - 2025)

Insight Molecular Diagnostics' Other Non Operating Income history spans 6 years, with the latest figure at $223000.0 for Q3 2025.

  • For Q3 2025, Other Non Operating Income rose 320.75% year-over-year to $223000.0; the TTM value through Sep 2025 reached $651000.0, up 24.24%, while the annual FY2024 figure was $462000.0, 38.74% up from the prior year.
  • Other Non Operating Income for Q3 2025 was $223000.0 at Insight Molecular Diagnostics, up from $125000.0 in the prior quarter.
  • Across five years, Other Non Operating Income topped out at $278000.0 in Q2 2022 and bottomed at -$1.2 million in Q4 2021.
  • The 5-year median for Other Non Operating Income is $53000.0 (2024), against an average of -$3473.7.
  • The largest annual shift saw Other Non Operating Income tumbled 29350.0% in 2021 before it soared 15400.0% in 2024.
  • A 5-year view of Other Non Operating Income shows it stood at -$1.2 million in 2021, then soared by 68.51% to -$371000.0 in 2022, then skyrocketed by 156.06% to $208000.0 in 2023, then fell by 29.81% to $146000.0 in 2024, then skyrocketed by 52.74% to $223000.0 in 2025.
  • Per Business Quant, the three most recent readings for IMDX's Other Non Operating Income are $223000.0 (Q3 2025), $125000.0 (Q2 2025), and $157000.0 (Q1 2025).